Assyro AI

FDA Orange Book · active-ingredient family

Temazepam

Temazepam is approved as 1 brand and 23 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:RESTORIL · NDA 018163

1

Brand (NDA)

23

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule

ProductApplicantApplicationTEApproved
RESTORILRLD×4SPECGX LLCNDA 018163ABOct 25, 1991

Generic (ANDA) products (23)

ProductApplicantApplicationTEApproved
TEMAZEPAM×4ALKEM LABS LTDANDA 217875ABAug 24, 2023
TEMAZEPAM×4ALEMBICANDA 211542ABNov 23, 2018
TEMAZEPAM×4AMNEAL PHARMSANDA 203482ABMay 23, 2016
TEMAZEPAM×4PRINSTON INCANDA 201781ABJun 04, 2015
TEMAZEPAM×3NOVEL LABS INCANDA 071457ABJun 22, 2012
TEMAZEPAM×4AUROBINDO PHARMA USAANDA 070920May 21, 2010
TEMAZEPAM×2SUN PHARM INDUSTRIESANDA 071175Sep 14, 2009
TEMAZEPAMSUN PHARM INDUSTRIESANDA 078581Sep 08, 2009
TEMAZEPAMWATSON LABSANDA 071446May 21, 1993
TEMAZEPAMWATSON LABSANDA 071447May 21, 1993
TEMAZEPAMDURAMED PHARMS BARRANDA 071708Sep 29, 1988
TEMAZEPAMDURAMED PHARMS BARRANDA 071709Sep 29, 1988
TEMAZEPAMCHARTWELL RXANDA 071427ABJan 12, 1988
TEMAZEPAMCHARTWELL RXANDA 071428ABJan 12, 1988
TEMAZEPAM×2ACTAVIS ELIZABETHANDA 071620ABAug 07, 1987
TEMAZEPAMNOVEL LABS INCANDA 071456ABApr 21, 1987
TEMAZEPAMWATSON LABSANDA 070383Mar 23, 1987
TEMAZEPAMWATSON LABSANDA 070384Mar 23, 1987
TEMAZEPAMSUN PHARM INDUSTRIESANDA 071174Jul 10, 1986
TEMAZEPAMUSL PHARMAANDA 070489Jul 07, 1986
TEMAZEPAMUSL PHARMAANDA 070490Jul 07, 1986
TEMAZQUANTUM PHARMICSANDA 070564Oct 15, 1985
TEMAZQUANTUM PHARMICSANDA 070547Oct 15, 1985

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Temazepam — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.